Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in Overweight and Obese Patients With Type 2 Diabetes Mellitus Managed With Oral Hypoglycemic Agent(s)

NCT00603291 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00603291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00603291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of Lorcaserin Hydrochloride in Overweight and Obese Patients With Type 2 Diabetes Mellitus Managed With Oral Hypoglycemic Agent(s)
Lead sponsor
Eisai Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2007
Completion date
October 31, 2010
Enrollment
604 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obesity